Anna Norhammar
About
In The Last Decade
Anna Norhammar
127 papers receiving 5.9k citations
Hit Papers
Peers
Comparison fields: 5 of 128
- Endocrinology, Diabetes and Metabolism 4.1k
- Cardiology and Cardiovascular Medicine 2.5k
- Molecular Biology 1.5k
- Surgery 1.1k
- Epidemiology 643
Countries citing papers authored by Anna Norhammar
This map shows the geographic impact of Anna Norhammar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Norhammar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Norhammar more than expected).
Fields of papers citing papers by Anna Norhammar
This network shows the impact of papers produced by Anna Norhammar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Norhammar. The network helps show where Anna Norhammar may publish in the future.
Co-authorship network of co-authors of Anna Norhammar
This figure shows the co-authorship network connecting the top 25 collaborators of Anna Norhammar. A scholar is included among the top collaborators of Anna Norhammar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Norhammar. Anna Norhammar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 0 | |
| 3 | 0 | |
| 4 | 7 | |
| 5 | 3 | |
| 6 | 4 | |
| 7 | 36 | |
| 8 | 30 | |
| 9 | Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs breakdown → | 604 |
| 10 | Doubled healthcare costs of type 2 diabetes mellitus during years 2006-2014 : a nationwide cost-of-illness study in Sweden | 1 |
| 11 | Glycosylated haemoglobin predicts mortality in patients with heart failure and unknown diabetes : insights from the Swedish Heart Failure registry (SwedeHF) | 1 |
| 12 | First-line and intensified treatment with glucose lowering drugs in the Swedish type 2 diabetes population | 1 |
| 13 | Second-line treatment with sulfonylurea compared to DPP4 inhibitors is associated with risk of cardiovascular disease, all-cause mortality and severe hypoglycaemia | 0 |
| 14 | EACPR country of the month initiative: Sweden. | 1 |
| 15 | Second-line treatment with sulfonylurea compared to DPP4 inhibitors demonstrated associations with earlier treatment intensification with insulin | 4 |
| 16 | Impact of diabetes mellitus on heart failure with reduced ejection fraction : a Swedish registry based analysis | 1 |
| 17 | 39 | |
| 18 | 2 | |
| 19 | 2 | |
| 20 | 237 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.